On July 29, 2025 LTZ Therapeutics ("LTZ"), an immunotherapy-focused biotechnology company, reported a strategic research collaboration with Eli Lilly and Company ("Lilly") to develop novel myeloid engager therapeutics against selected targets for the treatment of diseases with high unmet need (Press release, LTZ Therapeutics, JUL 29, 2025, View Source [SID1234654618]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, LTZ will receive a double-digit million USD upfront payment and an equity investment in the company. LTZ is also eligible to receive preclinical, clinical, regulatory and commercial milestone payments, in addition to tiered royalties on net sales of any resulting commercialized products.

"We are thrilled to enter into a strategic partnership with Lilly, a global leader in immunology and oncology," said Robert Li, Founder and CEO of LTZ. "This collaboration represents a pivotal step towards our mission in harnessing the potential of myeloid biology to address diseases with high unmet need. With Lilly’s expertise and global reach, we’re accelerating the development of our myeloid engager programs and we’re one step closer to bringing transformative therapies to the patients who need them most."